Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized multicenter trial of sunitinib monotherapy in platinum-refractory or platinum-resistant ovarian cancer
2007-003089-16Phase 2Completed
- Sponsor
- AGO Research
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sunitinib in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by AGO Research. Primary endpoint: Confirmed tumor response. Started Jul 2008; status: completed.
02
Drugs
sunitinib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2007-003089-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003089-16.